WX [WuXi PharmaTech (Cayman)] SC 13E3/A: (Original Filing)
[]
WX [WuXi PharmaTech (Cayman)] SC 13G/A: (Original Filing)
[(Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) November 30, 2015 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY 4. CITIZENSHIP]
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] SC 13E3/A: EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20,
[EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20, 2015 for WUXI MERGER LIMITED arranged by PING AN BANK CO., LTD. ( DEVELOPMENT BANK CO., LTD. ( as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( as Facility Agent and PING AN BANK CO., LTD. ( as Security Agent CONTENTS CLAUSE PAGE SECTION 1 INTERPRETATION 1 1. Definitions] [EXECUTION VERSION U.S.$300,000,000 FACILITY AGREEMENT November 20, dated for GROUP & CLOUD LIMITED arranged by PING AN BANK CO., LTD. ( DEVELOPMENT BANK CO., LTD. ( as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( as Facility Agent and PING AN BANK CO., LTD. ( as Security Agent CONTENTS CLAUSE PAGE SECTION 1 INTERPRETATION 1 1. Definitions] [SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER Amendment Parent Merger Sub Company This SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER, dated as of November 20, 2015 (this Agreement WHEREAS, Parent, Merger Sub and the Company desire to enter into this Amendment, which shall amend the Agreement in accordance with the terms and conditions set forth] []
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS 3 4 2
[Form 6-K TABLE OF CONTENTS 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS 3 4 12 2 WuXi PharmaTech (Cayman) Inc. Edward Hu]
WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS 3 4 12
[Form 6-K TABLE OF CONTENTS 3 4 12 2 WuXi PharmaTech (Cayman) Inc. Edward Hu]
WX [WuXi PharmaTech (Cayman)] SC 13E3/A: (Original Filing)
[PROXY STATEMENT OF THE COMPANY October 20, 2015 Shareholders of WuXi PharmaTech (Cayman) Inc. Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of WuXi PharmaTech (Cayman) Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the Company), to be held] [EXECUTION VERSION SECOND AMENDED AND RESTATED CONSORTIUM AGREEMENT THIS SECOND AMENDED AND RESTATED CONSORTIUM AGREEMENT Agreement Chairman ABG Boyu Initial Sponsors G&C Temasek Hillhouse PRC Ping An G&C IV Co-Founder Equity LP Yunfeng Sequoia Legend Capital SPDBI Principal Consortium Member Principal Consortium Members Party Sponsor Parties Sponsors WHEREAS Original Consortium Agreement Transaction Company NYSE Exchange Act WHEREAS A&R Consortium Agreement] [EXECUTION VERSION CONFIDENTIAL AMENDED AND RESTATED INTERIM INVESTORS AGREEMENT Agreement Chairman Management Roll-over Entity ABG Boyu Temasek Hillhouse Ping An G&C IV Co-Founder Equity LP Yunfeng Sequoia Legend Capital SPDBI Equity Sponsor Equity Sponsors Investor Investors Holdco Parent Merger Sub Parties Party This Amended and Restated Interim Investors Agreement (this RECITALS Original Interim Investors Agreement WHEREAS, on August 14,] []
